# Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

> **NCT07284290** · PHASE4 · RECRUITING · sponsor: **Virginia Commonwealth University** · enrollment: 120 (estimated)

## Conditions studied

- Dementia With Lewy Bodies
- Parkinson Disease Dementia
- Healthy Controls

## Interventions

- **PROCEDURE:** Syn-One skin biopsy
- **DIAGNOSTIC_TEST:** Multi modal MRI
- **DIAGNOSTIC_TEST:** Assessment of dynamic EEG features over 48-hour periods across all study aims
- **DIAGNOSTIC_TEST:** Plasma biomarkers
- **DRUG:** Galantamine HBr extended-release 8mg capsules (8mg ER).

## Key facts

- **NCT ID:** NCT07284290
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2029-11
- **Final completion:** 2029-11
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284290, "Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07284290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*